MorphoSys (MOR) Competitors $18.96 0.00 (0.00%) As of 07/3/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock MOR vs. ASND, VTRS, QGEN, MRNA, BPMC, VRNA, BBIO, ROIV, RVMD, and ELANShould you be buying MorphoSys stock or one of its competitors? The main competitors of MorphoSys include Ascendis Pharma A/S (ASND), Viatris (VTRS), Qiagen (QGEN), Moderna (MRNA), Blueprint Medicines (BPMC), Verona Pharma PLC American Depositary Share (VRNA), BridgeBio Pharma (BBIO), Roivant Sciences (ROIV), Revolution Medicines (RVMD), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry. MorphoSys vs. Its Competitors Ascendis Pharma A/S Viatris Qiagen Moderna Blueprint Medicines Verona Pharma PLC American Depositary Share BridgeBio Pharma Roivant Sciences Revolution Medicines Elanco Animal Health Ascendis Pharma A/S (NASDAQ:ASND) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations. Is ASND or MOR more profitable? Ascendis Pharma A/S has a net margin of -93.22% compared to MorphoSys' net margin of -226.79%. Ascendis Pharma A/S's return on equity of 0.00% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets Ascendis Pharma A/S-93.22% N/A -33.29% MorphoSys -226.79%-694.31%-22.55% Do institutionals and insiders believe in ASND or MOR? 18.4% of MorphoSys shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by company insiders. Comparatively, 0.1% of MorphoSys shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has higher earnings and valuation, ASND or MOR? MorphoSys has lower revenue, but higher earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAscendis Pharma A/S$393.54M27.04-$409.12M-$6.28-27.72MorphoSys$238.28M11.99-$205.35M-$3.48-5.45 Do analysts prefer ASND or MOR? Ascendis Pharma A/S presently has a consensus price target of $220.67, indicating a potential upside of 26.77%. Given Ascendis Pharma A/S's stronger consensus rating and higher probable upside, research analysts clearly believe Ascendis Pharma A/S is more favorable than MorphoSys.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ascendis Pharma A/S 0 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 3.00MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to ASND or MOR? In the previous week, Ascendis Pharma A/S had 5 more articles in the media than MorphoSys. MarketBeat recorded 6 mentions for Ascendis Pharma A/S and 1 mentions for MorphoSys. Ascendis Pharma A/S's average media sentiment score of 0.55 beat MorphoSys' score of -0.71 indicating that Ascendis Pharma A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive MorphoSys 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Which has more volatility and risk, ASND or MOR? Ascendis Pharma A/S has a beta of 0.38, meaning that its stock price is 62% less volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. SummaryAscendis Pharma A/S beats MorphoSys on 10 of the 16 factors compared between the two stocks. Get MorphoSys News Delivered to You Automatically Sign up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MOR vs. The Competition Export to ExcelMetricMorphoSysPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.86B$839.47M$5.55B$9.05BDividend YieldN/A4.84%5.24%4.01%P/E Ratio-5.451.1527.6120.23Price / Sales11.99228.55417.23118.52Price / CashN/A23.4436.8958.10Price / Book54.176.328.035.67Net Income-$205.35M-$27.99M$3.18B$249.21M7 Day PerformanceN/A2.11%2.93%3.28%1 Month PerformanceN/A10.13%3.75%5.55%1 Year Performance1.94%11.60%35.20%21.09% MorphoSys Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730News CoverageASNDAscendis Pharma A/S3.5057 of 5 stars$175.78-0.6%$220.67+25.5%+29.7%$10.81B$393.54M-27.991,017News CoverageAnalyst ForecastVTRSViatris2.6727 of 5 stars$8.85-0.2%$10.40+17.5%-10.9%$10.41B$14.33B-2.7932,000QGENQiagen4.0478 of 5 stars$46.72-0.1%$47.74+2.2%+22.5%$10.39B$1.98B117.145,765Dividend AnnouncementMRNAModerna4.3797 of 5 stars$25.67-0.9%$46.61+81.6%-73.7%$10.02B$3.24B-2.945,800Options VolumeBPMCBlueprint Medicines1.5646 of 5 stars$128.40+0.2%$128.06-0.3%+17.6%$8.28B$508.82M-51.98640High Trading VolumeVRNAVerona Pharma PLC American Depositary Share2.6057 of 5 stars$97.05+2.9%$101.10+4.2%+480.4%$8.03B$42.28M-48.5330Positive NewsAnalyst ForecastBBIOBridgeBio Pharma4.6902 of 5 stars$42.17+1.1%$56.67+34.4%+74.8%$7.92B$221.90M-11.95400News CoverageInsider TradeAnalyst RevisionROIVRoivant Sciences1.5415 of 5 stars$11.50+0.4%$17.50+52.2%+3.5%$7.78B$29.05M-46.00860RVMDRevolution Medicines4.5785 of 5 stars$40.04+1.0%$67.08+67.5%+0.2%$7.39B$11.58M-10.01250Analyst RevisionELANElanco Animal Health2.4121 of 5 stars$13.36-0.7%$15.17+13.5%+3.6%$6.68B$4.44B18.059,000News CoverageAnalyst Forecast Related Companies and Tools Related Companies ASND Competitors VTRS Competitors QGEN Competitors MRNA Competitors BPMC Competitors VRNA Competitors BBIO Competitors ROIV Competitors RVMD Competitors ELAN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MOR) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MorphoSys AG Please log in to your account or sign up in order to add this asset to your watchlist. Share MorphoSys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MOR Stock Alerts